Local cellular immune response plays a key role in protecting chickens against hepatitis-hydropericardium syndrome (HHS) by vaccination with a recombinant fowl adenovirus (FAdV) chimeric fiber protein

0301 basic medicine Immunity, Cellular Recombinant Fusion Proteins Adenoviridae Infections Aviadenovirus Immunology Vaccination cellular immunity RC581-607 Pericardial Effusion chimeric fiber vaccine Adenoviridae Hepatitis 3. Good health FAdV-4 hepatitis-hydropericardium syndrome 03 medical and health sciences humoral immunity fowl adenovirus Animals Immunologic diseases. Allergy Chickens Poultry Diseases
DOI: 10.3389/fimmu.2022.1026233 Publication Date: 2022-10-28T13:33:22Z
ABSTRACT
Fowl adenovirus (FAdV)-induced diseases hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH) have been affecting the poultry industry with increasing severity in last two decades. Recently, a subunit vaccine based on chimeric fiber protein epitopes from different fowl serotypes (named crecFib-4/11) has shown to confer simultaneous protection against both HHS IBH. However, underlying immune mechanisms chickens are still enigmatic, especially because of frequently absent neutralizing response despite high levels protection. In this study, we investigated kinetics humoral cellular responses specific pathogen-free after vaccination crecFib-4/11 and/or challenge HHS-causing strain, systemic level, as well locally target lymphoid organs. The was assessed via enzyme-linked immunosorbent assay (ELISA) virus neutralization test serum, while determined by phenotyping using flow cytometry. Although induced serum antibodies, confirmed ELISA, such antibodies exhibited no pre-challenge activity FAdV-4. Nevertheless, immunized birds experienced significant B cell increase liver upon challenge, remaining throughout experiment. Furthermore, stimulated proliferation cytotoxic T lymphocytes, earlier circulation blood compared control subsequent spleen. Overall, these findings imply that relies prominent local organs, instead circulating antibodies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (12)